The drugmaker, which specializes in producing insulin products, reportedly is looking to layoffs to shore up finances as it faces an “uncertain and unpredictable” market in the U.S.
The new cost-savings plan is largely driven by the windstorms mounting in the U.S. over drug pricing, especially Novo’s insulin products, which already have come under fire for their high costs.
“We are operating in a dynamic environment that brings new challenges and opportunities every day, which means we continually assess and adjust plans as needed. And whenever we make important decisions, we will communicate them at the appropriate time,” Novo Nordisk CEO Lars Fruergaard Jørgensen told Endpoints.
Novo is expected to announce the full cost-cutting plan in August, alongside its second quarter results.
More articles on supply chain:
Bayer hikes price of 2 cancer drugs by $1k per month
Hospira recalls opioid overdose antidote
FDA confirms 5 more patient deaths linked to balloon obesity devices: 5 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
